NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
05 Nov 2019

Anaconda biomed announces first-in-human study of Next-generation thrombectomy system

Anaconda Biomed has announced the completion of initial patient cases in a first-in-human study at Hospital Vall d’Hebron in Barcelona.
30 Oct 2019

Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis

Sanifit, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has met its primary endpoint.
17 Oct 2019

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics, today announces that its lead drug candidate, leriglitazone, has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and Drug Administration.
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting<
15 Oct 2019

Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting

Light-Activated AU-011 has the Potential to be the First FDA Approved Therapy for the Primary Treatment of Choroidal Melanoma
09 Oct 2019

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients with Friedreich’s Ataxia.
01 Oct 2019

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma B.V. today announces that it has expanded its senior team with two appointments. Dr. Juliane Bernholz has joined as Chief Operating Officer (COO), and Ms. Kristie Bass as VP Clinical Operations (VP Clin Ops).
11 Sep 2019

CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device

CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD).
Xeltis’ closes €10.5 million Series D financing<
05 Sep 2019

Xeltis’ closes €10.5 million Series D financing

The funding was provided by existing institutional and private investors, including all venture capital funds (VCs) already financing the company.
16 Jul 2019

AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma B.V. (‘AM-Pharma, today announces that it has raised €116m [$133m] from a European syndicate of new and existing investors.
Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise<
26 Jun 2019

Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise

Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка